title: Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer.
abstract: OBJECTIVE
  The purpose of this study was to determine if a suboptimal cytoreduction can be predicted preoperatively in women with advanced ovarian cancer.
  
  
  METHODS
  All women with stage III/IV epithelial ovarian cancer treated with initial surgery at our hospital between January 1, 1995 and January 1, 2003 were eligible; 56 patients met inclusion criteria and underwent retrospective chart review. Statistical analysis was performed using SPSS.
  
  
  RESULTS
  Twenty-nine women (52%) had optimal cytoreduction (OC), and 27 (48%) had suboptimal cytoreduction (SC). Women in the SC group had higher median CA-125 values at surgery (954 SC vs 597 OC, P = .07). Three sites of disease on preoperative CT were reported more frequently in the SC patients; omentum (P = .007), parietal peritoneum (P = .096), and ascites (P = .093).
  
  
  CONCLUSIONS
  A suboptimal cytoreduction confers no survival advantage to women with advanced ovarian cancer. Thus, these patients may be the best candidates for initial chemotherapy, and identifying them preoperatively becomes important.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, Charlottesville, VA 22908-0712, USA. ee6c@virginia.edu
authors.forename: Elise N
authors.initials: EN
authors.lastname: Everett
authors.forename: Cara C
authors.initials: CC
authors.lastname: Heuser
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Pastore
authors.forename: Willie A
authors.initials: WA
authors.lastname: Anderson
authors.forename: Laurel W
authors.initials: LW
authors.lastname: Rice
authors.forename: William P
authors.initials: WP
authors.lastname: Irvin
authors.forename: Peyton T
authors.initials: PT
authors.lastname: Taylor
mesh_terms: D000328:Adult; D000368:Aged; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D018394:CA-125 Antigen